Belgium Unveils New Leniency Guidelines
Client Alert | 1 min read | 10.24.07
CompetitionLaw360
Belgium has revealed a new set of guidelines for its leniency program, hoping to better employ the competition tool that has enabled U.S., EU and Asian antitrust authorities to unravel some of the world’s most notorious cartels. Belgium published a revamped version of its 2004 leniency initiative in the Belgium State Gazette, indicating a desire to keep up with the strides and various refinements that have been made to such programs over the years.
Under the new legislation, Belgium will reportedly accept oral leniency and implement a marker system, an increasingly popular feature among immunity programs. The acceptance of oral or other nonwritten statements from cartel members applying for leniency will help to protect companies concerned about producing hard documents that could later be subpoenaed or discoverable in civil litigation elsewhere, especially in the U.S. The marker system would enable cartel members to come forward and reserve places in line for leniency even before they have gathered information. This, regulators believe, will help them to capitalize on cartel members’ distrustful paranoia and ensure that members would come forward quickly.
Though the council has received an estimated 20 immunity applications since the program was first introduced in 2004, most of those were the result of companies applying for leniency in several jurisdictions, also known as double-dips. Seeking to toughen up the program, the council began the process of revising its leniency program back in September, inviting practitioners to comment on the process for the first time ever.
Insights
Client Alert | 3 min read | 11.17.26
CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs
On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.
Client Alert | 9 min read | 11.17.26
Priorities and Prospects for AI Legislation in the New Congress
Client Alert | 8 min read | 11.16.26
OCC’s AI Examiner Framework: How Banks’ AI Use Can Trigger Legal Liability and Supervisory Exposure
Client Alert | 3 min read | 11.13.26
Massachusetts Trade Secret Preliminary Injunctions: Prove the Harm, Tailor the Relief
